Evotec Shares Plunge to Multi-Year Low Amid Restructuring Plan

Evotec's Horizon restructuring overshadowed by disappointing 2026 revenue and EBITDA guidance, sending shares to a 5-year low ahead of a crucial April update.

Investors delivered a harsh verdict on Evotec SE's newly announced corporate overhaul, sending the biotechnology firm's stock to its lowest level in five years. The market's negative reaction centered on a disappointing financial outlook for the coming year, overshadowing the company's "Horizon" transformation program intended to streamline operations.

Disappointing Forecast Overshadows Restructuring

Presented on March 10, the Horizon initiative outlines significant cost-cutting measures, including the reduction of up to 800 positions and the consolidation of its site network from 14 locations to 10. This involves the complete closure of its Munich facility. Management targets annualized savings of approximately €75 million by 2027.

However, the capital market focused squarely on the guidance for the current fiscal year. For 2026, Evotec anticipates group revenues between €700 million and €780 million, a figure that falls below the €788 million reported for the prior year. More alarmingly, its adjusted EBITDA is projected to be in a range of zero to €40 million. Even the upper end of the revenue forecast sits meaningfully below the existing analyst consensus. In a research note, RBC analyst Charles Weston stated that while the medium-term ambitions were unsurprising, the weak operational target for 2026 was difficult to reconcile. The company itself has framed 2026 as a transitional period, with the first operational improvements not anticipated until the latter half of the year.

A Company of Two Halves

Evotec's 2025 results underscore a stark internal divergence. Its core Drug Discovery & Preclinical Development segment saw revenue decline by 13% to about €529 million, posting a negative adjusted EBITDA of -€12 million. In contrast, the Just – Evotec Biologics unit performed strongly, with revenue climbing roughly 40% to €259 million and contributing approximately €53 million in EBITDA.

This paints a picture of a corporation that is simultaneously contracting and expanding, depending on which division is under scrutiny.

Market Awaits Crucial Update

Looking further ahead, Evotec's strategic goals include surpassing €1 billion in revenue by 2030 and achieving a 20% adjusted EBITDA margin by 2028. The feasibility of this trajectory hinges on the speed of realized savings and the sustained growth of the Biologics division. The equity, currently trading at €4.14, has lost nearly half its value since its 52-week high of €8.32 in May 2025.

All eyes are now on April 8, when Evotec will release its final audited results for 2025 and provide more detailed medium-term targets. This upcoming announcement will serve as a critical first assessment of whether the Horizon program represents a genuine strategic pivot or merely another corporate restructuring plan.